568599-43-9

Upstream product

• 568599-40-6 3,4-difluoro-2-[(4-ethynyl-2-fluorophenyl)amino]benzoic acid 

Downstream Products

• 568600-14-6 N-(2,2-dimethyl-[1,3]dioxan-5-yloxy)-2-(4-ethyl-2-fluoro-phenyl amino)-3,4-difluoro-benzamide 
• 568600-10-2 N-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-benzamide 
• 568599-37-1 2-[(4-ethyl-2-fluorophenyl )amino]-3,4-difluoro-N-(2-hydroxyethoxy)benzamide 
• 718619-81-9 2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-benzoic acid hydrazide 

Relevant academic research and scientific papers

MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES

This invention provides substituted Phenyl-(2-[1,3,4]thiadiazol-2-yl-phenyl)-amine and (2-[1,3,4]Oxadiazol-2-yl-phenyl)phenyl-amine compounds which act as inhibitors of MAPKIERK Kinase ("MEK") enzymes and pharmaceutical compositions and methods for their use in immunomodulation and in the treatment and alleviation of inflammation, and proliferative diseases such as cancer and restenosis.

N-(4-substituted phenyl)-anthranilic acid hydroxamate esters

The present invention relates to oxygenated esters of 4-substituted-phenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.